Table 2 Small-vessel vasculitis and intensive care management
Data (N = 82 patients) | |
|---|---|
Small-vessel vasculitis management | |
Number of patients receiving glucocorticoid induction treatment | 74 (90) |
Number of days | 3.0 (3.0–3.0) |
Total dose, mg methylprednisolone equivalents | 1500 (1500–3000) |
Number of patients receiving daily glucocorticoids after induction treatment | 79 (96) |
Number of patients receiving plasma exchange | 63 (77) |
Number of sessions | 7.0 (5.0–7.0) |
Number of patients receiving cyclophosphamide pulse | 82 (100) |
Induction dose, mg | 1000 (800–1000) |
Number of patients receiving rituximab | 3 (4) |
ICU management | |
Number of patients receiving mechanical ventilationa | 42 (51) |
Duration of mechanical ventilation, days | 11.5 (8.0–22.5) |
Number of patients receiving venovenous extracorporeal membrane oxygenation | 6 (7) |
Number of patients receiving catecholamines | 25 (31) |
Duration of catecholamine administration, days | 7.0 (3.0–18.5) |
Number of patients receiving renal replacement therapy in ICU | 58 (71) |
Duration of renal replacement therapy in ICU, days | 13.0 (8.0–20.75) |
Number of patients receiving renal replacement therapy before ICU stay | 11 (13) |
Number of patients receiving renal replacement therapy after ICU stay | 28 (34) |